![](https://www.diabetesnews.com/wp-content/uploads/2017/01/beautiful-pills-1453117-150x150.jpg)
A study in Diabetes Care showed that patients with poorly controlled type 2 diabetes who received a combination of exenatide and pioglitazone had a threefold lower rate of hypoglycemia, a one-percentage-point greater reduction in A1C and less weight gain than those in the basal-bolus insulin therapy group.